Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.

被引：50
|
作者：
Sullivan, Ryan J.
Hong, David S.
Tolcher, Anthony W.
Patnaik, Amita
Shapiro, Geoffrey
Chmielowski, Bartosz
Ribas, Antoni
Brail, Les H.
Roberts, Jennifer
Lee, Lucy
O'Connell, Brenda
Kutok, Jeffrey Lorne
Mahabhashyam, Suresh
Ullmann, Claudio Dansky
Postow, Michael A.
Wolchok, Jedd D.
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[6] Infin Pharmaceut Inc, Cambridge, MA USA
[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3013
引用
收藏
页数：1
相关论文
共 50 条
  • [41] First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors.
    Mahalingam, Devalingam
    Patel, Manish R.
    Sachdev, Jasgit C.
    Hart, Lowell L.
    Halama, Neils
    Ramanathan, Ramesh K.
    Sarantopoulos, John
    Liu, Xiaochun
    Yazji, Salim
    Jaeger, Dirk
    Adib, Deyaa Rafaat
    Kerschbaumer, Randolf
    Tsimberidou, Apostolia Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] A phase 1/2, first-in-human trial of ZB131, a novel antibody targeting cancer-specific plectin (CSP) in advanced solid tumors.
    Sommerhalder, David
    Piha-Paul, Sarina A.
    Pelster, Meredith
    Borad, Mitesh J.
    Vandross, Andrae Lavon
    Spira, Alexander I.
    Perez, Samantha
    Brinton, Lindsey
    Kelly, Kimberly
    Ramanathan, Ramesh K.
    Reilley, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors.
    Harb, Wael A.
    Adjei, Alex A.
    Beeram, Murali
    Pipas, J. Marc
    Chen, Sharon
    Valencia, Andrea
    Rimkunas, Victoria
    McClure, Ty
    Kearns, Jeffrey D.
    Nering, Rachel
    Lieu, Christopher Hanyoung
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFß inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors
    Robbrecht, Debbie
    Doger, Bernard
    Grob, Jean-Jacques
    Bechter, Oliver Edgar
    De Miguel, Maria J.
    Vieito, Maria
    Schadendorf, Dirk
    Curigliano, Giuseppe
    Borbath, Ivan
    Butler, Marcus O.
    Rodriguez-Vida, Alejo
    Miller, Wilson H.
    Lin, Tun Tun
    Masson, Nina
    Pouzin, Clemence
    Wang, Rui
    Demers, Brigitte
    Amrate, Amele
    Abbadessa, Giovanni
    Simonelli, Matteo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors.
    Ghazaly, Essam Ahmed
    Joel, Simon
    Gribben, John G.
    Mohammad, Tariq
    Emiloju, Oluwadunni
    Stavraka, Chara
    Hopkins, Tom
    Gabra, Hani
    Wasan, Harpreet
    Habib, Nagy A.
    Leonard, Robert C. F.
    McGuigan, Christopher
    Slusarczyk, Magdalena
    Blagden, Sarah Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] First-in-human, dose-escalation, safety, and PK study of a novel 5T4-ADC in patients with advanced solid tumors.
    Shapiro, Geoffrey
    LoRusso, Patricia
    Vaishampayan, Ulka N.
    Kittaneh, Muaiad
    Hilton, John Frederick
    Cleary, James M.
    Velastegui, Karen
    Xuan, Dawei
    Hua, Steven
    Shazer, Ronald L.
    Borghaei, Hossein
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors.
    Xu, Jian-Ming
    Wang, Yan
    Chen, Yu-ling
    Jia, Ru
    Shen, Lin
    Wang, Jian
    Sai, Yang
    Qi, Chuan
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] A phase I/II, two-part, multicenter, first-in-human study of DS-7300a in patients with advanced solid malignant tumors.
    Bendell, Johanna C.
    Doi, Toshihiko
    Patel, Manish R.
    Piha-Paul, Sarina Anne
    Sen, Shiraj
    Shimizu, Toshio
    Cheng, Ben
    Mekan, Sabeen F.
    Myobatake, Yusuke
    Okuda, Yasuyuki
    Serbest, Gul
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Liang, Yan
    Harvey, R. Donald
    Fu, Siqing
    Weitao, Yao
    Qin, Yan-Ru
    Zhang, Xiaojing
    Henry, Jason Timothy
    Zou, Qingping
    Shan, Boyao
    Liang, Pan
    Wang, Chen
    Li, Wenjia
    Pamuklar, Zehra Nurgul
    Pei, Yi
    Chang, Zhiwei
    Wang, Jiaqiang
    Piha-Paul, Sarina A.
    Bhave, Manali A.
    Yin, Yongmei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.
    Schwartz, Gary K.
    Adkins, Douglas
    Heist, Rebecca Suk
    Abbott, Maura
    Barber, Stephanie L.
    Chao, Richard C.
    Neuteboom, Saskia T. C.
    Chen, Isan
    Christensen, James
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345